脑脉利颗粒治疗不同亚型急性脑梗死的临床疗效观察

Efficacy of Naomaili granule in the treatment of different subtypes of acute cerebral infarction

目的研究脑脉利颗粒治疗不同类型急性脑梗死患者的临床效果及安全性。方法收集2019年6月-12月122例急性脑梗死住院患者,随机分为对照组56例,观察组66例。对照组按急性缺血性脑卒中诊治指南治疗,观察组在此基础上给予脑脉利颗粒治疗,两组均按TOAST分型标准进行分型。比较对照组及观察组不同亚型脑脉利颗粒治疗前后的NIHSS评分、Barthel指数评分以及不良反应。结果与对照组比较,观察组治疗后3 w的NIHSS评分降低,Barthel指数评分升高(P<0.05)。大动脉粥样硬化型(LAA)、小血管闭塞型(SAO)、其他明确原因型(OD)、不明原因型(UND)的NIHSS评分明显下降(P<0.05),Barthel指数评分明显升高(P<0.05),其中LAA改善最明显(P<0.05);而心源性栓塞型(CE)的评分改善在对照组和观察组的差异无统计学意义(P>0.05)。结论脑脉利颗粒对急性脑梗死临床效果良好,能有效改善TOAST病因分型中LAA、SAO、OD、UND亚型的神经功能以及日常生活能力。

Objective To study the efficacy and safety of Naomaili granule in patients with different subtypes of acute cerebral infarction.Methods A total of 122 hospitalized patients with acute cerebral infarction from June to December 2019 were randomly divided into control group(n=56)and observation group(n=66).The control group was treated according to the guidelines for the diagnosis and treatment of acute ischemic stroke,while the observation group was treated with Naomaili granule besides the guidelines.The two groups were classified according to the TOAST criteria.Before and after treatment,NIHSS score and BI score were compared,and adverse reaction was evaluated.Results Compared with the control group,the NIHSS score of observation group was decreased while BI score was increased after 21 days of treatment(P<0.05).After the treatment,the NIHSS score of the subtype of large-artery therosclerosis(LAA)、small-artery occlusion(SAO)、cardioembolism(OD)、otherdetermined cause(OD)and undetermined cause(UND)was decreased while BI scores was increased(P<0.05).However,LAA subtype improved more obviously(P<0.05),while the change of CE subtype had no statistical significance(P>0.05).Conclusion Naomaili granule has a good effect on acute cerebral infarction and it can improve the nervous function and activities of daily living for the subtypes of LAA,SAO,OD and UND according to the TOAST criteria.